Meet Max, and learn about the rare immune disorder called hemophagocytic lymphohistiocytosis, better known as HLH. In patients with HLH, the immune system does not work as it should, and often requires a bone marrow transplant. Cincinnati Children’s is one of the most experienced facilities in the nation in treating HLH and the clinical and research pioneers at Cincinnati Children’s HLH Center of Excellence are committed to changing the outcome for children who have it.
Unfortunately, few physicians are knowledgeable about HLH, and it is often misdiagnosed or diagnosed too late. Without access to effective treatment, primarily bone marrow transplantation (BMT), most patients with HLH die.
As the most experienced facility in the nation in treating HLH, Cincinnati Children’s has assembled a team of researchers, physicians, families who have faced an HLH diagnosis and philanthropists to create the HLH Center of Excellence.
The center focuses on four core priorities:
Education and awareness
Family support
While HLH is rare, Cincinnati Children’s treats a large population of children with HLH. The clinical and research pioneers at Cincinnati Children’s are committed to changing the outcome for children with HLH.
Discovery through innovative research is essential to developing the medical breakthroughs that improve outcomes for children with HLH.
Currently, Cincinnati Children's is conducting many research studies that could change the face of diagnosis and care for HLH. We are conducting two HLH research studies, one focusing on a new drug to control the disease and another on a treatment regimen combining two previous approaches to treat patients with HLH. Also, read about a presentation by Michael B. Jordan, MD, about the NI-0501 trial at the ASH Annual Meeting and Exposition in December 2015.